UA118289C2 - Гомогенна композиція для перорального введення, яка містить омега-3 поліненасичені жирні кислоти і ресвератрол - Google Patents
Гомогенна композиція для перорального введення, яка містить омега-3 поліненасичені жирні кислоти і ресвератрол Download PDFInfo
- Publication number
- UA118289C2 UA118289C2 UAA201613087A UAA201613087A UA118289C2 UA 118289 C2 UA118289 C2 UA 118289C2 UA A201613087 A UAA201613087 A UA A201613087A UA A201613087 A UAA201613087 A UA A201613087A UA 118289 C2 UA118289 C2 UA 118289C2
- Authority
- UA
- Ukraine
- Prior art keywords
- resveratrol
- composition according
- fatty acids
- months
- pufa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001941.5A EP2952209B1 (en) | 2014-06-04 | 2014-06-04 | Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration |
| PCT/EP2015/056524 WO2015185238A1 (en) | 2014-06-04 | 2015-03-26 | Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA118289C2 true UA118289C2 (uk) | 2018-12-26 |
Family
ID=50884651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201613087A UA118289C2 (uk) | 2014-06-04 | 2015-03-26 | Гомогенна композиція для перорального введення, яка містить омега-3 поліненасичені жирні кислоти і ресвератрол |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10300035B2 (enExample) |
| EP (1) | EP2952209B1 (enExample) |
| JP (1) | JP6552526B2 (enExample) |
| CN (1) | CN106456783B (enExample) |
| AU (1) | AU2015271277A1 (enExample) |
| CA (1) | CA2943000A1 (enExample) |
| EA (1) | EA032717B1 (enExample) |
| ES (1) | ES2666836T3 (enExample) |
| MX (1) | MX361765B (enExample) |
| PL (1) | PL2952209T3 (enExample) |
| PT (1) | PT2952209T (enExample) |
| UA (1) | UA118289C2 (enExample) |
| WO (1) | WO2015185238A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250006294A (ko) * | 2022-05-06 | 2025-01-10 | 선포레스트 (베이징) 바이오팜 엘티디 | 세포막 막횡단 수송과 유동성을 조절하는 탄소사슬 물질, 제조 및 응용 |
| CN114569726B (zh) * | 2022-05-06 | 2022-10-28 | 太阳雨林(北京)生物医药有限公司 | 预防、阻止或治疗微生物感染的复合物及制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1306722B1 (it) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
| ITRM20020562A1 (it) | 2002-11-06 | 2004-05-07 | Sigma Tau Ind Farmaceuti | Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza. |
| DK1863570T3 (da) * | 2005-03-11 | 2011-06-20 | Recon Oil Ind Private Ltd | Synergistisk varmestabilt oliemedium med eicosapentaensyre (EPA) og decosahexaensyre (DHA) |
| DE202008003509U1 (de) * | 2008-03-12 | 2009-10-15 | Langhoff, Gertrud | Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung |
| KR101100078B1 (ko) * | 2008-03-27 | 2011-12-29 | 홉킨스바이오연구센터(주) | 관절염 치료를 위한 약제학적 조성물 |
| CN102665698A (zh) | 2009-12-23 | 2012-09-12 | 迪菲安特制药有限责任公司 | 可用于治疗心血管疾病的联合组合物 |
| WO2011120530A1 (en) | 2010-03-31 | 2011-10-06 | Lifecycle Phama A/S | Porous tablets as carriers for liquid formulations |
| WO2011162802A1 (en) * | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| IT1400695B1 (it) | 2010-06-21 | 2013-06-28 | Labomar S R L | Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle. |
| CN102228089B (zh) * | 2011-06-22 | 2013-02-20 | 刘升胜 | 一种天然复合食用植物健脑营养饮料 |
| KR101418980B1 (ko) * | 2012-04-24 | 2014-07-11 | (주)바이오제닉스 | 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법 |
| EP2664329A1 (de) * | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Ophthalmologisches Vehikelsystem |
| WO2014095628A1 (en) * | 2012-12-17 | 2014-06-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) |
-
2014
- 2014-06-04 EP EP14001941.5A patent/EP2952209B1/en active Active
- 2014-06-04 PT PT140019415T patent/PT2952209T/pt unknown
- 2014-06-04 ES ES14001941.5T patent/ES2666836T3/es active Active
- 2014-06-04 PL PL14001941T patent/PL2952209T3/pl unknown
-
2015
- 2015-03-26 CA CA2943000A patent/CA2943000A1/en not_active Abandoned
- 2015-03-26 JP JP2016570876A patent/JP6552526B2/ja not_active Expired - Fee Related
- 2015-03-26 CN CN201580029857.9A patent/CN106456783B/zh not_active Expired - Fee Related
- 2015-03-26 EA EA201692398A patent/EA032717B1/ru not_active IP Right Cessation
- 2015-03-26 UA UAA201613087A patent/UA118289C2/uk unknown
- 2015-03-26 WO PCT/EP2015/056524 patent/WO2015185238A1/en not_active Ceased
- 2015-03-26 US US15/316,151 patent/US10300035B2/en active Active
- 2015-03-26 AU AU2015271277A patent/AU2015271277A1/en not_active Abandoned
- 2015-03-26 MX MX2016013190A patent/MX361765B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2666836T3 (es) | 2018-05-08 |
| EP2952209B1 (en) | 2018-03-28 |
| CA2943000A1 (en) | 2015-12-10 |
| US10300035B2 (en) | 2019-05-28 |
| CN106456783A (zh) | 2017-02-22 |
| PL2952209T3 (pl) | 2018-07-31 |
| CN106456783B (zh) | 2020-06-12 |
| JP2017516820A (ja) | 2017-06-22 |
| EA032717B1 (ru) | 2019-07-31 |
| MX361765B (es) | 2018-12-17 |
| JP6552526B2 (ja) | 2019-07-31 |
| PT2952209T (pt) | 2018-05-09 |
| WO2015185238A1 (en) | 2015-12-10 |
| EA201692398A1 (ru) | 2017-04-28 |
| US20170119720A1 (en) | 2017-05-04 |
| AU2015271277A1 (en) | 2016-11-10 |
| EP2952209A1 (en) | 2015-12-09 |
| MX2016013190A (es) | 2017-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2709612C2 (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| EP3248599B1 (en) | Omega-3 fatty acid self-emulsifying composition | |
| US20210128510A1 (en) | Self-emulsifying composition of omega3 fatty acid | |
| JP6896019B2 (ja) | 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法 | |
| ES2585066T3 (es) | Composiciones para el tratamiento de trastornos neurológicos | |
| UA118289C2 (uk) | Гомогенна композиція для перорального введення, яка містить омега-3 поліненасичені жирні кислоти і ресвератрол | |
| JP2002226368A (ja) | 赤血球の酸化的損傷抑制剤 | |
| WO2014095628A1 (en) | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) | |
| JP2023113819A (ja) | 脂質組み合わせ | |
| JP2025502795A (ja) | Ｅｐａ－ｅｅナノ脂質組成物、その製剤、調製方法及び使用 | |
| US20200330422A1 (en) | Formulations for Treating and/or Preventing Disease | |
| UA119174C2 (uk) | Тверді склади, які містять омега-3 і ресвератрол | |
| JP2023524877A (ja) | カンナビノイドの使用および製剤 | |
| JP2023534362A (ja) | カンナビノイドの使用および製剤 | |
| RU2645092C1 (ru) | Гепатопротекторная инъекционная фармацевтическая композиция на основе силимарина и наночастиц селена | |
| TWI788582B (zh) | ω３脂肪酸之自體乳化製劑及自體乳化組成物 | |
| WO2015185240A1 (en) | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |